Edgewise Therapeutics, Inc.
EWTX
Classificação em ações
#3979
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Preço da ação
$38.12
Última sincronização: 2026-10-19
Valor de mercado
$4.10B
Variação (1 dia)
2.50%
Variação (1 ano)
147.69%
País
US
Negociar Edgewise Therapeutics, Inc. (EWTX)
Categoria
Healthcare
Rácio P/S de Edgewise Therapeutics, Inc. (EWTX)
Rácio P/S em October 2026 TTM: 0.00
De acordo com os relatórios financeiros mais recentes e o preço das ações da Edgewise Therapeutics, Inc., o rácio P/S atual (TTM) é 0.00. No final de 2023, o rácio P/S era 0.00.
Histórico do rácio P/S da Edgewise Therapeutics, Inc. de 2019 a 2026
Rácio P/S no final de cada ano
| Ano | Rácio P/S | Alterar |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
Rácio P/S de empresas semelhantes ou concorrentes
| Empresa | Rácio P/S | Diferença do rácio P/S | País |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
